A call to action The white paper includes five calls to action for the FDA and Congress: FDA should stop allowing compounders to produce GLP-1 drugs with added ingredients and claim them as personalized medicine
We further characterized the expression of activated or inhibitory receptors on lymphocytes after L-Cn stimulation
This treatment option can be used as primary and secondary prevention
[11] Zepbound pens remain covered on some plans (requires prior authorization) Some stricter plans still exclude all Zepbound products entirely Sleep apnea coverage has less strict requirements than other BCBS plans BCBS Texas The 2026 formulary lists still include Zepbound for weight management, suggesting continued coverage with prior authorization
These data indicated that berberine activated GLP-1/GLP-1R/PKA signaling pathway in TC1/6 cell
As the GLP-1-based drug development landscape continues to unfold at dramatic pace, AMRA is at the forefront of designing effective biomarkers that elucidate insights beyond weight loss, supporting emerging therapies in demonstrating their safety and efficacy across a number of disease areas, including cardiovascular disease
